Vorasidenib
Commons · Question 12370 · Tabled 4 Nov 2024 · Department of Health and Social Care · Official record
Answered 11 Nov 2024
Question
Asked by Andrew Rosindell
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of vorasdenib for treatment of low-grade gliomas.
Answer
Answered by Karin Smyth, 11 Nov 2024
It is critical that medicines used in the United Kingdom are safe and effective and as such, medicines cannot be marketed in the UK without a marketing authorisation. These are granted by the Medicines and Healthcare products Regulatory Agency (MHRA) whic...